If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
11 May 2021 MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.
8 November 2018 Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
11 May 2021 MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.
8 November 2018 Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
11 May 2021 MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.
8 November 2018 Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
